Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia

American Journal of Health-System Pharmacy

Volumn 65, Issue 1, 2008, Pages 42-48

  Strutton, David R ^a   Gutierrez, Benjamin ^b   Bianchette, Christopher M ^c  

^a PFIZER INC   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Antipsychotic agents; Dosage; Hospitals; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SHORT ACTING DRUG; ZIPRASIDONE;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DRUG COST; DRUG DOSE ESCALATION; DRUG USE; EMERGENCY WARD; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MENTAL HEALTH SERVICE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 37849026100     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060635     Document Type: Article

References (27)

1. Wu E, Birnbaum H, Shi L et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005; 66:1122-9.
2. National Institute of Mental Health. Schizophrenia. www.nimh.nih.gov/ health/publications/schizophrenia/schizophrenia-booklet - 2006.pdf (accessed 2007 Oct 10).
3. Mauskopf JA, David K, Grainger DL et al. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry. 1999; 60:14-9.
4. Salkever D, Domino ME, Burns BJ et al. Assertive community treatment for people with severe mental illness: the effect on hospital use and costs. Health Serv Res. 1999; 34:577-601.
5. Buckley PF, Wirshing DA, Bhushan P et al. Lack of insight in schizophrenia. CNS Drugs. 2007; 21:129-41.
6. Lacro JP, Dunn LB, Dolder CR et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63:892-909.
7. HCUPnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. www.hcupnet.ahrq. gov (accessed 2007 Nov 7).
8. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, 2nd ed. www.psych.org/psych_pract/treatg/pg/ SchizPG-Complete-Feb04.pdf (accessed 2007 Oct 5).
9. Correll CU, Leucht S, Kane JM. Reduced risk of tardive dyskinesia with second-generation antipsychotics: a systematic review of one-year studies. Am J Psychiatry. 2004; 161:414-25.
10. Markoweitz JS, Brown DS, Moore TR. Atypical antipsychotics part 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999; 33:73-85.
11. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res. 1999; 35(suppl):S101-9.
12. Leucht S, Pitschel-Walz G, Abraham D et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35:51-68.
13. Sartorius N, Fleischhacker WW, Gjerris A et al. The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry. 2002; 14: S1-51.
14. National Institute of Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. www.nice.org.uk/guidance/index.jsp?action=byID&o=10916 (accessed 2007 Nov 7).
15. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ. 2005; 24:1-31.
16. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209-23.
17. Lindenauer PK, Pekow P, Wang K et al. Perioperative beta-blocker therapy and mortality after major non-cardiac surgery. N Engl J Med. 2005; 353:349-61.
18. Averill RF, Goldfield NI, Muldoon J et al. A closer look at all-patient refined DRGs. J AHIMA. 2002; 73:46-50.
19. Clozaril (clozapine) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2005 May.
20. Abilify (aripiprazole) package insert. Princeton, NJ, and Tokyo, Japan: Bristol-Myers Squibb Co. and Otsuka America Pharmaceuticals, Inc.; 2005 Dec.
21. Geodon (ziprasidone hydrochloride) package insert. New York: Pfizer Inc.; 2005 May.
22. Risperdal (risperidone) package insert. Titusville, NJ: Janssen Pharmaceutica; 2005 Nov.
23. Seroquel (quetiapine fumarate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals; 2005 Dec.
24. Zyprexa (olanzapine) package insert. Indianapolis: Eli Lilly and Company; 2006 Mar.
25. Haldol product information. Physicians' desk reference. 60th ed. Montvale, NJ: Thomson PDR; 2006:2443-5.
26. Mladsi DM, Grogg AL, Irish WD et al. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004; 20:1883-93.
27. Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res. 2003; 31:188-96.